A 28-year-old woman with PCOS (confirmed by Rotterdam criteria) presents with primary infertility for 2 years. She is anovulatory with normal BMI (22 kg/m²), no hirsutism, and normal androgen levels. Pelvic ultrasound confirms polycystic ovaries. She has been on lifestyle modification for 6 months without improvement in ovulation. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **lean PCOS** (normal BMI, normal androgens, anovulatory) seeking fertility after 6 months of failed lifestyle modification. The next step is **pharmacological ovulation induction**, and current evidence supports **letrozole** as the first-line agent. ## Why Letrozole is Now First-Line in PCOS **Key Point:** Letrozole (an aromatase inhibitor) has replaced clomiphene citrate as the **first-line ovulation induction agent** in anovulatory PCOS, based on landmark evidence from the NEJM 2014 Legro et al. trial and subsequent ESHRE/ASRM 2023 guidelines. **High-Yield:** Letrozole mechanism: - Inhibits aromatase → reduces peripheral estrogen synthesis - Removes negative estrogen feedback at hypothalamus/pituitary → ↑ FSH secretion → mono-follicular development - Shorter half-life than clomiphene → less anti-estrogenic effect on endometrium and cervical mucus - **Live birth rate: ~27.5% per cycle vs. ~19.1% for clomiphene** (Legro et al., NEJM 2014) ## Dosing and Protocol | Step | Agent | Dose | Timing | |------|-------|------|--------| | **First-line** | **Letrozole** | **2.5 mg/day** | **Days 3–7 of cycle** | | Second-line | Clomiphene citrate | 50 mg/day | Days 3–7 | | Third-line | Gonadotropins (FSH) | Individualized | Specialist-guided | | Fourth-line | Laparoscopic ovarian drilling | — | Clomiphene/letrozole failure | | Last resort | IVF | — | All else failed | **Clinical Pearl:** The ESHRE International Evidence-Based Guideline on PCOS (2023) and ACOG explicitly recommend **letrozole as first-line** pharmacological ovulation induction in PCOS due to superior live birth rates, better endometrial receptivity, and a more favorable side-effect profile compared to clomiphene citrate. ## Comparison: Letrozole vs. Clomiphene Citrate | Feature | Letrozole | Clomiphene Citrate | |---------|----------|--------------------| | **Current first-line (ESHRE 2023)** | **Yes** | No (second-line) | | **Mechanism** | Aromatase inhibitor; ↑ FSH | SERM; blocks estrogen feedback | | **Live birth rate** | ~27.5% per cycle | ~19.1% per cycle | | **Endometrial thickness** | Preserved | May be thinned (anti-estrogenic) | | **Cervical mucus** | Preserved | May be hostile | | **Half-life** | Short (~45 hrs) | Long (~5–7 days) | | **Multiple pregnancy risk** | Lower | Higher | ## Why Other Options Are Incorrect - **Option A (Clomiphene citrate):** Previously first-line, but now superseded by letrozole per current ESHRE/ASRM guidelines due to inferior live birth rates. - **Option B (Diagnostic laparoscopy):** Not indicated as the *next* step; tubal assessment (HSG) is appropriate before ovulation induction, but laparoscopy is invasive and reserved for suspected tubal/peritoneal pathology after non-invasive workup. - **Option D (IVF):** Reserved for cases where ovulation induction has failed, or when there is severe male factor infertility or bilateral tubal occlusion. Premature at this stage. **High-Yield Reference:** Legro RS et al. "Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome." *NEJM* 2014; 371:119–129. ESHRE PCOS Guideline 2023.